The Medical Letter on Drugs and Therapeutics
A 4-Drug Combination (Stribild) for HIV
The full article is available to subscribers Subscriber Login   
Revised 1/3/13: In the “Drug Interactions” paragraph, the word “oral” has been inserted before “midazolam” in the 3rd sentence.

The FDA has approved a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) elvitegravir, the pharmacokinetic enhancer cobicistat, and the nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) emtricitabine and tenofovir disoproxil fumarate (Stribild – Gilead) for treatment of HIV-1 infection in antiretroviral treament-naïve adults. Elvitegravir is the second INSTI to be approved by the FDA for use in HIV treatment; raltegravir (Isentress) was the first.1

FIRST-LINE TREATMENT OF HIV — Antiretroviral treatment regimens usually include a "backbone" and a "base". Recommended choices for first-line therapy of HIV infection, depending on the results of resistance testing, include a non-nucleoside reverse transcriptase inhibitor (NNRTI) such as efavirenz, a ritonavir-boosted protease inhibitor such as atazanavir, or an INSTI as the base, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: A 4-Drug Combination (Stribild) for HIV
Article code: 1404c
 Electronic, downloadable article - $25